308G/A and 238G/A polymorphisms in the TNF-α gene may not contribute to the risk of arthritis among Turkish psoriatic patients

[1]  E. Donadi,et al.  HLA‐C and TNF gene polymorphisms are associated with psoriasis in Brazilian patients , 2016, International journal of dermatology.

[2]  Xiaoming Liu,et al.  Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis. , 2015, International immunopharmacology.

[3]  C. Salvarani,et al.  The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis , 2015, The Journal of Rheumatology. Supplement.

[4]  A. Roussaki-Schulze,et al.  Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques. , 2015, Experimental and therapeutic medicine.

[5]  C. De Simone,et al.  TNF‐alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  A. Barton,et al.  Identifying a novel locus for psoriatic arthritis , 2015, Rheumatology.

[7]  T. Gheita,et al.  Clinical significance of serum TNFα and -308 G/A promoter polymorphism in rheumatoid arthritis , 2015 .

[8]  M. Suárez-Fariñas,et al.  Comparative Genomic Profiling of Synovium Versus Skin Lesions in Psoriatic Arthritis , 2015, Arthritis & rheumatology.

[9]  V. Trajković,et al.  TNF, IL12B, and IFNG Gene Polymorphisms in Serbian Patients with Psoriasis , 2015, Annals of dermatology.

[10]  P. Mandich,et al.  TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. , 2014, The Journal of investigative dermatology.

[11]  R. Mössner,et al.  Complex role of TNF variants in psoriatic arthritis and treatment response to anti-TNF therapy: evidence and concepts. , 2014, The Journal of investigative dermatology.

[12]  H. Hussein,et al.  Serum tumor necrosis factor alpha (TNF-α) level in patients with Behçet’s disease: Relation to clinical manifestations and disease activity , 2014 .

[13]  D. Cai,et al.  Associations between Tumor Necrosis Factor-α Polymorphisms and Risk of Psoriasis: A Meta-Analysis , 2013, PloS one.

[14]  Juan Li,et al.  Single Nucleotide Polymorphisms in the Tumor Necrosis Factor-Alpha Gene Promoter Region Alter the Risk of Psoriasis Vulgaris and Psoriatic Arthritis: A Meta-Analysis , 2013, PloS one.

[15]  T. Gheita,et al.  Clinical significance of serum TNFα and -308 G/A promoter polymorphism and serum Il-6 and -174 G/C promoter polymorphism in systemic lupus erythematosus patients , 2012 .

[16]  S. Ibrahim,et al.  Association of asymptomatic hyperuricemia and endothelial dysfunction in psoriatic arthritis , 2012 .

[17]  M. Lebwohl,et al.  Potential complications associated with the use of biologic agents for psoriasis. , 2007, Dermatologic clinics.

[18]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[19]  D. Gladman,et al.  TNFα polymorphisms and risk of psoriatic arthritis , 2005 .

[20]  R. Stern,et al.  Epidemiology of psoriatic arthritis in the population of the United States. , 2005, Journal of the American Academy of Dermatology.

[21]  E. Berardesca,et al.  Cytokine profiles during infliximab monotherapy in psoriatic arthritis , 2005, The British journal of dermatology.

[22]  B. Bresnihan,et al.  Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. , 2003, Arthritis and rheumatism.

[23]  J. Kalden,et al.  Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. , 2002, Arthritis and rheumatism.

[24]  C. López-Larrea,et al.  MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. , 2002, The Journal of rheumatology.

[25]  A. Cambon-Thomsen,et al.  Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. A. El-Rahman,et al.  Ultrasonographic evaluation of lower limb enthesis in patients with early spondyloarthropathies , 2013 .

[27]  I. König,et al.  Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. , 2005, The Journal of investigative dermatology.

[28]  S. D'alfonso,et al.  A polymorphic variation in a putative regulation box of the TNFA promoter region , 2004, Immunogenetics.

[29]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.